Evidence map›Paper›PMID 41703006›Full record

ArticleScientific reports2026

Autism spectrum disorder-associated Sema5A p.Arg676Cys drives Arf6/FE65 signaling and aberrant cell morphogenesis.

Mikito Takahashi, Hideji Yako, Yuki Miyamoto, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Junji Yamauchi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Hesperetin Rescues Amyloid Beta-Induced Defects in Neurite Outgrowth UnderInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mikito Takahashi *Laboratory of Molecular Neuroscience and Neurology, Hachioji, Tokyo, Japan.
Hideji Yako *Laboratory of Molecular Neuroscience and Neurology, Hachioji, Tokyo, Japan.
Yuki MiyamotoLaboratory of Molecular Neuroscience and Neurology, Hachioji, Tokyo, Japan.
Mutsuko Kukimoto-NiinoLaboratory for Protein Functional and Structural Biology, Center for Biosystems Dynamics Research, RIKEN, Tsurumi, Yokohama, 230-0045, Japan.
Mikako ShirouzuLaboratory for Protein Functional and Structural Biology, Center for Biosystems Dynamics Research, RIKEN, Tsurumi, Yokohama, 230-0045, Japan.
Junji YamauchiLaboratory of Molecular Neuroscience and Neurology, Hachioji, Tokyo, Japan. yamauchi@toyaku.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by impairments in social interaction, challenges with communication, and repetitive behaviors. Genetic mutations associated with ASD can either activate or inactivate the responsible proteins, affecting neuronal morphogenesis and contributing to the disorder’s hallmark features. However, the molecular mechanisms driving these changes remain incompletely understood. Here, we report for the first time that the small GTP/GDP-binding protein Arf6 and FE65, which act together with the genetically conserved engulfment and cell motility 2 (ELMO2) signalosome to control Rac1, underlie the excessive neuronal process elongation phenotype associated with the ASD-linked semaphorin-5 A (Sema5A) Arg676-to-Cys protein (p.Arg676Cys). Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas13-mediated knockdown of Arf6 or FE65 reversed the excessively elongated processes in primary cortical neurons. Similar results were obtained in the N1E-115 cell line, a model capable of neuronal morphological differentiation. Moreover, expression of the ELMO2-binding domain of FE65 restored Rac1 activity required for process elongation, recapitulating the effects seen in the knockdown experiments. These findings suggest that signaling through FE65 specifically couples Sema5A p.Arg676Cy to the ELMO2 signalosome molecule, driving excessively elongated processes with elevated Rac1 activity. One or more of these molecules may provide possible therapeutic targets for correcting the cellular phenotypes associated with the Sema5A p.Arg676Cys mutation in ASD.

Indexed as

ADP-Ribosylation FactorsAutism Spectrum DisorderMembrane ProteinsMorphogenesisNerve Tissue ProteinsSemaphorinsAdaptor Proteins, Signal TransducingADP-Ribosylation Factor 6AnimalsHumansMiceNeuronsrac1 GTP-Binding ProteinSignal TransductionAdaptor Proteins, Signal TransducingADP-Ribosylation Factor 6ADP-Ribosylation FactorsARF6 protein, humanArf6 protein, mouseMembrane ProteinsNerve Tissue Proteinsrac1 GTP-Binding ProteinSEMA5A protein, humanSemaphorinsArf6Autism spectrum disorderELMO2FE65MorphogenesisSema5A

Identifiers

PMID41703006
PMCPMC13003097

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.